Parnax Lab

Parnax Lab Depreciation & Amortization

The Depreciation & Amortization of Parnax Lab (506128.BO) as of Nov 4, 2026 is 73.78 M INR. In the previous year, Depreciation & Amortization was 69.64 M INR — a change of 5.94% (higher).

Depreciation & Amortization

73.78 MINR

YoY

5.94%

Last updated:

Depreciation & Amortization of Parnax Lab is 2025 73.78 M INR. Depreciation & Amortization of Parnax Lab was 2024 69.64 M INR. It decreases by 5.94% higher compared to the previous year.

The Parnax Lab Depreciation & Amortization history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Depreciation & Amortization
Date
Depreciation & Amortization
Jan 1, 2018
37.40 M INR
Jan 1, 2019
38.24 M INR
Jan 1, 2020
44.59 M INR
Jan 1, 2021
51.60 M INR
Jan 1, 2022
58.66 M INR
Jan 1, 2023
65.29 M INR
Jan 1, 2024
69.64 M INR
Jan 1, 2025
73.78 M INR
The Parnax Lab Depreciation & Amortization history
YEARDepreciation & AmortizationYoY
73.78 MINR+5.94%
69.64 MINR+6.67%
65.29 MINR+11.31%
58.66 MINR+13.68%
51.60 MINR+15.70%
44.59 MINR+16.63%
38.24 MINR+2.23%
37.40 MINR-0.32%
37.52 MINR+29.60%
28.95 MINR-3.27%
29.93 MINR+42.53%
21.00 MINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Parnax Lab Stock analysis

What does Parnax Lab do? Parnax Lab Ltd. generates revenue through manufacturing and exporting pharmaceutical formulations, including cough expectorants, antacids, anti-histamines, multi-vitamins, enzyme preparations, pediatric formulations, geriatric special formulations, highly viscous products, and suspensions. The company trades pharmaceuticals and medicinal products, focusing on high-volume oral formulations for diverse consumer segments. Naxpar Pharma Private Limited serves as its subsidiary in these operations. The firm's primary customers are likely healthcare providers, pharmacies, and distributors within the pharmaceutical industry, though specific buyer details are not disclosed. Parnax Lab Ltd. operates through the pharmaceutical formulations segment, emphasizing export-driven manufacturing and trading activities. Its product portfolio targets various health needs, from pediatric to geriatric care, with a strong focus on oral delivery systems. Parnax Lab is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Parnax Lab stock

Depreciation & Amortization of Parnax Lab is 73.78 M INR in 2025.

Depreciation & Amortization of Parnax Lab changed from 69.64 M INR to 73.78 M INR, representing a 5.94% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Depreciation & Amortization Parnax Lab since 2006 – with annual values, charts, and detailed analysis.

Depreciation & Amortization represents the allocation of the cost of tangible and intangible assets over their useful lives.

Depreciation & Amortization's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Depreciation & Amortization's Parnax Lab historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Parnax Lab

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Parnax Lab